Syncom Formulation (India)
Syncom Formulation (India) Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Syncom Formulation (India)
Start SIPSyncom Formulation (India) F&O
Syncom Formulation (India) Investment Rating
-
Master Rating:
-
Syncom Formulations India has an operating revenue of Rs. 221.51 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of 12% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 7 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 91 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 57 | 54 | 51 | 58 |
| Operating Expenses Qtr Cr | 51 | 50 | 48 | 56 |
| Operating Profit Qtr Cr | 6 | 4 | 3 | 2 |
| Depreciation Qtr Cr | 1 | 1 | 1 | 1 |
| Interest Qtr Cr | 1 | 1 | 1 | 1 |
| Tax Qtr Cr | 2 | 2 | 1 | 1 |
| Net Profit Qtr Cr | 4 | 4 | 4 | 5 |
Syncom Formulation (India) Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 6.3
- 50 Day
- 6.89
- 100 Day
- 7.44
- 200 Day
- 8.03
- 20 Day
- 6.27
- 50 Day
- 7.05
- 100 Day
- 7.64
- 200 Day
- 8.04
Syncom Formulation (India) Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 6.12 |
| Second Resistance | 6.24 |
| Third Resistance | 6.33 |
| RSI | 31.44 |
| MFI | 20.4 |
| MACD Single Line | -0.33 |
| MACD | -0.31 |
| Support | |
|---|---|
| First Resistance | 5.91 |
| Second Resistance | 5.82 |
| Third Resistance | 5.7 |
Syncom Formulation (India) Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,118,591 | 69,800,078 | 62.4 |
| Week | 1,442,138 | 88,806,883 | 61.58 |
| 1 Month | 1,528,948 | 96,858,880 | 63.35 |
| 6 Month | 2,433,726 | 136,093,943 | 55.92 |
Syncom Formulation (India) Result Highlights
Syncom Formulation (India) Synopsis
NSE-Medical-Diversified
Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 219.66 Cr. and Equity Capital is Rs. 86.25 Cr. for the Year ended 31/03/2022. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.| Market Cap | 559 |
| Sales | 222 |
| Shares in Float | 46.06 |
| No of funds | 2 |
| Yield | 0.5 |
| Book Value | 2.31 |
| U/D Vol ratio | 0.3 |
| LTDebt / Equity | |
| Alpha | -0.2 |
| Beta | 0.86 |
Syncom Formulation (India)
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | |
| Mutual Funds | ||||
| Foreign Portfolio Investors | ||||
| Individual Investors | 45.02% | 44.92% | 44.86% | |
| Others | 4.41% | 4.51% | 4.57% |
Syncom Formulation (India) Management
| Name | Designation |
|---|---|
| Mr. Kedarmal Shankarlal Bankda | Executive Chairman |
| Mr. Vijay Shankarlal Bankda | Managing Director |
| Mrs. Rinki Ankit Bankda | Whole Time Director |
| Mr. Krishna Das Neema | Independent Director |
| Mr. Praveen Jindal | Independent Director |
| Mr. Vinod Kumar Kabra | Independent Director |
| Mrs. Ruchi Jindal | Addnl. Independent Woman Director |
Syncom Formulation (India) Forecast
Price Estimates
Syncom Formulation (India) FAQs
What is Share Price of Syncom Formulation (India) ?
Syncom Formulation (India) share price is ₹5 As on 25 March, 2023 | 06:50
What is the Market Cap of Syncom Formulation (India) ?
The Market Cap of Syncom Formulation (India) is ₹560.2 Cr As on 25 March, 2023 | 06:50
What is the P/E ratio of Syncom Formulation (India) ?
The P/E ratio of Syncom Formulation (India) is 34.2 As on 25 March, 2023 | 06:50
What is the PB ratio of Syncom Formulation (India) ?
The PB ratio of Syncom Formulation (India) is 2.5 As on 25 March, 2023 | 06:50